Stock Earnings

Question 1

What are Ascentage Pharma Group International's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Ascentage Pharma Group International has a total asset of $2,617, Net loss of $-405

Question 2

What are the key financial ratios for ASPHF?

Accepted Answer

Ascentage Pharma Group International's Current ratio is 1.11, has a Net margin is -41.32, sales per share of $3.24.

Question 3

How is Ascentage Pharma Group International's revenue broken down by segment or geography?

Accepted Answer

Ascentage Pharma Group International largest revenue segment is Intellectual Property Rights, at a revenue of 735,553,749 in the most earnings release.For geography, Switzerland is the primary market for Ascentage Pharma Group International, at a revenue of 735,553,749.

Question 4

Is Ascentage Pharma Group International profitable?

Accepted Answer

no, according to the latest financial statements, Ascentage Pharma Group International has a net loss of $-405

Question 5

Does Ascentage Pharma Group International have any liabilities?

Accepted Answer

yes, Ascentage Pharma Group International has liability of 2,353

Question 6

How many outstanding shares for Ascentage Pharma Group International?

Accepted Answer

Ascentage Pharma Group International has a total outstanding shares of 315.22

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	390	980	221	209	27	12
Revenue Growth (YoY)	-56.99%	343%	6%	674%	125%	-14%
Cost of Revenue	35	29	30	21	3	1
Gross Profit	354	951	191	187	24	10
Selling, General & Admin	393	331	376	328	191	130
Research & Development	1,002	913	706	743	766	564
Operating Expenses	1,507	1,325	1,065	1,040	917	698
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-1,143	-395	-932	-887	-832	-675
Income Tax Expense	15	10	-7	-4	-49	2
Net Income	-1,159	-405	-925	-882	-782	-677
Net Income Growth	222%	-56%	5%	13%	16%	-54%
Shares Outstanding (Diluted)	341.59	302.06	282.29	263.66	254.61	215.9
Shares Change (YoY)	17%	7%	7%	4%	18%	85%
EPS (Diluted)	-3.39	-1.34	-3.27	-3.34	-3.07	-3.13
EPS Growth	172%	-59%	-2%	9%	-2%	-75%
Free Cash Flow	-216	-135	-782	-890	-1,041	-861
Free Cash Flow Per Share	-0.63	-0.44	-2.77	-3.37	-4.08	-3.98
Gross Margin	90.76%	97.04%	86.42%	89.47%	88.88%	83.33%
Operating Margin	-295.38%	-38.16%	-395.47%	-407.65%	-3,307.4%	-5,725%
Profit Margin	-297.17%	-41.32%	-418.55%	-422%	-2,896.29%	-5,641.66%
Free Cash Flow Margin	-55.38%	-13.77%	-353.84%	-425.83%	-3,855.55%	-7,175%
EBITDA	-1,072	-281	-797	-791	-865	-660
EBITDA Margin	-274.87%	-28.67%	-360.63%	-378.46%	-3,203.7%	-5,500%
D&A For EBITDA	80	93	77	61	28	27
EBIT	-1,152	-374	-874	-852	-893	-687
EBIT Margin	-295.38%	-38.16%	-395.47%	-407.65%	-3,307.4%	-5,725%
Effective Tax Rate	-1.31%	-2.53%	0.75%	0.45%	5.88%	-0.29%

Ascentage Pharma Group International (ASPHF) Price

ASPHF Stock Price Chart

ASPHF Income

Follow-Up Questions